PTH and chronic kidney disease: Similarly, while cinacalcet was shown 10 y ago to markedly improve surrogate outcomes (both serum PTH and calcium by phosphorus product levels) in people with CKD [20], and observational analyses suggest an association between cinacalcet treatment and improved all-cause and cardiovascular mortality [17], until recently, randomized trial evidence systematically evaluating the effect of cinacalcet on clinical outcomes was not available.